Precision AQ - Investor Relations & External Communications’ Post

Did you miss out on our last webinar? Watch the full episode here: https://lnkd.in/eU7Vj8FD Be part of the conversation & join us for the final webinar in our series on February 27th 1-3pm ET! We will be exploring the future of therapeutics in genomic medicine. Register at https://lnkd.in/gppCGBgB #therapeutics #rarediseases #geneticcounseling #genechat

Genetic Biomarker Prediction Using Whole Slide Images and Prompts: A New Frontier in CRC Diagnosis *** PromptBio enhances genetic biomarker prediction by selecting relevant image patches from whole slide images, grouping them into specific pathological components, and modeling their interactions. This method, validated on significant datasets, achieved superior accuracy compared to other methods, showing promise for clinical applications. *** https://lnkd.in/e8gF6xjz

Most-Read Precision Medicine Stories in 2023: Immunotherapy, Lay Offs, Regulation, Adoption, Access. This year, stories about new targetable biomarkers and genetic testing tools, the impact of economic headwinds and regulation, and access disparities were most popular with readers. http://ow.ly/VqMf1057frq

Words cannot express how proud some of us are today, having been a part of this journey from the earliest of days. Special mention to the original scientific think-tank and my partners Bill Lundberg, Chad Cowan, Andrew Kernytsky, TJ Cradick, Ph.D. and Michelle Lin. It is even more remarkable to know that a journey we started almost a decade ago, is paving the way for so much more today, including the expansion into allogeneic transplants for curing hematological malignancies at companies like Vor Bio, that some of us privileged to be a part of. Long-live Genetic Medicines. Long-live good, rigorous Science! This is just the beginning. Read more from STAT

The new Fragment Sequencing approach developed by researchers at ETH Zurich is opening up new insights into single-cell transcriptomics, and expanding the scope of what we know about cell-to-cell interaction, disease progression and tumorigenesis. Read our summary of the study to learn more : 👉 https://lnkd.in/dRQDGZ6N #BDBiosciences #SingleCellAnalysis #SingleCell #SpatialBiology #Rhapsody #BD 

🚀 FDA Approves First CRISPR Therapy for Sickle Cell Disease: A Milestone in Genetic Medicine! With 19 genetic therapies now approved by the FDA, including CASGEVY (exagamglogene autotemcel) for sickle cell disease, the promise of genome editing is reaching new heights. However, with price tags exceeding $4 million per patient, access remains a significant challenge. A multi-disciplinary task force offers a roadmap to address these high costs by: - Reducing per-patient costs by tenfold - Proposing innovative pricing structures and business models - Leveraging academic licensing, manufacturing innovation, and supportive regulations The goal? To make these life-saving therapies more affordable and accessible to all patients. 🌍 #GeneTherapy #CRISPR #SickleCell #AffordableHealthcare #Innovation

Designed to detect single nucleotide variants, small insertions or deletions, deletion-insertions, and copy number variants, our whole exome sequencing test provides answers that profoundly impact a patient’s medical journey. Learn more. https://bit.ly/3v4eGXA

The new Fragment Sequencing approach developed by researchers at ETH Zurich is opening up new insights into single-cell transcriptomics, and expanding the scope of what we know about cell-to-cell interaction, disease progression and tumorigenesis. Read our summary of the study to learn more : 👉 https://lnkd.in/dRQDGZ6N #BDBiosciences #SingleCellAnalysis #SingleCell #SpatialBiology #Rhapsody #BD 

Top 10 Precision Medicine Stories in 2023: Immunotherapy, Lay Offs, Regulation, Adoption and Access. This year, stories about new targetable biomarkers and genetic testing tools, the impact of economic headwinds and regulation, and access disparities were most popular with readers. http://ow.ly/hqGx1057fmA

#longevitymedicine and compliance of #cellandgenetherapy #webinaralert Don't miss this panel live in 6 days' time, but even if you can't make it, register anyway and you'll receive a link to watch on demand.